Brief: Cellceutix to request meeting with FDA for phase 2 ovarian cancer study
26/10/2015 11:40
Oct 26 (Reuters) - Cellceutix Corp CTIX.PK : * To request meeting with FDA for phase 2 ovarian cancer study; company's first-in-human study defines the pharmacokinetic profile of Kevetrin * Source text for Eikon ID:nMKWjCV93a * Further company coverage CTIX.PK ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Innovation Pharmaceuticals
See all newsBrief: Innovation Pharmaceuticals Announces New Milestone At Beamed On Track To File 510(K) Submission To FDA In Q2 2024
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review